mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy

Large genes including several CRISPR-Cas modules, such as gene activators (CRISPRa), require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, intravitreal supplementation of ABCA4 via REVeRT improves retinal degeneration and function in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.

[1]  E. Becirovic,et al.  dCas9-VPR-mediated transcriptional activation of functionally equivalent genes for gene therapy , 2022, Nature Protocols.

[2]  E. Becirovic.  Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications , 2022, Cellular and Molecular Life Sciences.

[3]  Chady H Hakim,et al.  Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models , 2021, Nature Communications.

[4]  R. MacLaren,et al.  Therapy Approaches for Stargardt Disease , 2021, Biomolecules.

[5]  J. Scholefield,et al.  Prime editing – an update on the field , 2021, Gene Therapy.

[6]  L. Ayton,et al.  Gene therapy for inherited retinal diseases: progress and possibilities , 2021, Clinical & experimental optometry.

[7]  S. Priglinger,et al.  Gene Therapy for Inherited Retinal Disorders: Update on Clinical Trials , 2021, Klinische Monatsblätter für Augenheilkunde.

[8]  S. Priglinger,et al.  Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders , 2021, EMBO molecular medicine.

[9]  Sidi Chen,et al.  A web tool for the design of prime-editing guide RNAs , 2020, Nature biomedical engineering.

[10]  P. Charbel Issa,et al.  Quantitative Fundus Autofluorescence in ABCA4-related retinopathy - Functional Relevance and Genotype-Phenotype Correlation. , 2020, American journal of ophthalmology.

[11]  S. Tsang,et al.  Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  C. Wahl-Schott,et al.  A gene therapy for inherited blindness using dCas9-VPR–mediated transcriptional activation , 2020, Science Advances.

[13]  A. Auricchio,et al.  Large gene delivery to the retina with AAV vectors: are we there yet? , 2020, Gene Therapy.

[14]  Olivia J. Scheideler,et al.  The delivery challenge: fulfilling the promise of therapeutic genome editing , 2020, Nature Biotechnology.

[15]  F. Zhang,et al.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors , 2020, Cell.

[16]  W. Woods,et al.  Treatment of a Mouse Model of ALS by In Vivo Base Editing. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  David R. Liu,et al.  Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses , 2019, Nature Biomedical Engineering.

[18]  D. Kullmann,et al.  dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  M. Biel,et al.  Enigmatic rhodopsin mutation creates an exceptionally strong splice acceptor site. , 2019, Human molecular genetics.

[20]  David R. Liu,et al.  Search-and-replace genome editing without double-strand breaks or donor DNA , 2019, Nature.

[21]  S. Prescott,et al.  A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene , 2019, Nature.

[22]  Carel B. Hoyng,et al.  Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina , 2019, Science Translational Medicine.

[23]  P. Charbel Issa,et al.  An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4-/- Mice. , 2019, Human gene therapy.

[24]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[25]  Navneet Matharu,et al.  CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency , 2019, Science.

[26]  D. Duan,et al.  Design of AAV Vectors for Delivery of Large or Multiple Transgenes. , 2019, Methods in molecular biology.

[27]  M. Robinson,et al.  Treatment of a metabolic liver disease by in vivo genome base editing in adult mice , 2018, Nature Medicine.

[28]  Eugene Chung,et al.  Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy , 2018, Nature Biotechnology.

[29]  C. R. Esteban,et al.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation , 2017, Cell.

[30]  Livia S. Carvalho,et al.  Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting , 2017, Front. Neurosci..

[31]  V. J. Planelles-Herrero,et al.  Myosin 7 and its adaptors link cadherins to actin , 2017, Nature Communications.

[32]  Prashant Mali,et al.  A multifunctional AAV–CRISPR–Cas9 and its host response , 2016, Nature Methods.

[33]  C. Wahl-Schott,et al.  AAV Vectors for FRET-Based Analysis of Protein-Protein Interactions in Photoreceptor Outer Segments , 2016, Front. Neurosci..

[34]  Feng Zhang,et al.  Orthogonal gene knock out and activation with a catalytically active Cas9 nuclease , 2015, Nature Biotechnology.

[35]  G. Church,et al.  Cas9 gRNA engineering for genome editing, activation and repression , 2015, Nature Methods.

[36]  Tom W Muir,et al.  Inteins: Nature's Gift to Protein Chemists. , 2014, Chemical science.

[37]  M. Bacci,et al.  Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors , 2014, Gene Therapy.

[38]  R. Polishchuk,et al.  Effective delivery of large genes to the retina by dual AAV vectors , 2013, EMBO molecular medicine.

[39]  Ulrich Schraermeyer,et al.  Fundus autofluorescence in the Abca4(-/-) mouse model of Stargardt disease--correlation with accumulation of A2E, retinal function, and histology. , 2013, Investigative ophthalmology & visual science.

[40]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[41]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[42]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  Deniz Dalkara,et al.  Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  K. Palczewski,et al.  Limited roles of Rdh8, Rdh12, and Abca4 in all-trans-retinal clearance in mouse retina. , 2009, Investigative ophthalmology & visual science.

[45]  W. Hauswirth,et al.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  K. Palczewski,et al.  Retinopathy in Mice Induced by Disrupted All-trans-retinal Clearance* , 2008, Journal of Biological Chemistry.

[47]  Jürgen Götz,et al.  Primary support cultures of hippocampal and substantia nigra neurons , 2008, Nature Protocols.

[48]  D. Duan,et al.  Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  Tom W Muir,et al.  Protein ligation: an enabling technology for the biophysical analysis of proteins , 2006, Nature Methods.

[50]  Jianming Xu.  Preparation, culture, and immortalization of mouse embryonic fibroblasts. , 2005, Current protocols in molecular biology.

[51]  R. Crystal,et al.  In vivo trans-splicing of 5' and 3' segments of pre-mRNA directed by corresponding DNA sequences delivered by gene transfer. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  J. Bennett,et al.  Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. , 2003, Human gene therapy.

[53]  D. Duan,et al.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Duan,et al.  A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation , 2000, Nature Medicine.

[55]  Yulong Zhang,et al.  Concatamerization of Adeno-Associated Virus Circular Genomes Occurs through Intermolecular Recombination , 1999, Journal of Virology.

[56]  D. Birch,et al.  Insights into the Function of Rim Protein in Photoreceptors and Etiology of Stargardt's Disease from the Phenotype in abcr Knockout Mice , 1999, Cell.

[57]  M. Al-Ubaidi,et al.  Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter , 1992, The Journal of cell biology.

[58]  P. Sharp,et al.  Recombinant retroviruses encoding simian virus 40 large T antigen and polyomavirus large and middle T antigens , 1986, Molecular and cellular biology.